To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Paul Capital invests in Indian drugmaker
The US-based firm will use its royalty fund to help the company develop a US portfolio of dermatology drugs.
